公开(公告)号：EP2317994A2

公开(公告)日：2011-05-11

申请号：EP09800677.8

申请日：2009-07-23

申请人： Massachusetts Institute of Technology ,  The General Hospital Corporation

发明人： TSAI, Li-Huei ,  HAGGARTY, Stephen ,  KIM, Dohoon

IPC分类号： A61K31/16 ,  C07C259/04

CPC分类号： A61K31/675 ,  A61K31/122 ,  A61K31/16 ,  A61K31/198 ,  A61K31/352 ,  A61K31/366 ,  A61K31/662 ,  C07D223/16 ,  C07D311/30 ,  C07D311/80 ,  C07D493/18

摘要： The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDACl activators. Exemplary HDACl activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5- chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.